|
Correlation of HER-2, ER and PR status with clinicopathological data |
||||||
| HER-2 over-expression |
ER Positive |
PR Positive |
||||
| n (%) |
p |
n (%) |
p |
n (%) |
p |
|
|
|
||||||
| Age |
0.28 |
0.002 |
0. 76 |
|||
| ≤ 50 years |
17 (21.3) |
38 (47.5) |
43 (53.8) |
|||
| > 50 years |
11 (14.7) |
54 (72) |
38 (51.4) |
|||
| Tumor size |
0.104 |
0.129 |
0.72 |
|||
| ≤ 5 cm |
18 (15.3) |
74 (62.7) |
63 (53.4) |
|||
| > 5 cm |
10 (27) |
18 (48.6) |
18 (50) |
|||
| Histologic type |
0.33 |
0.31 |
0.47 |
|||
| Ductal |
22 (16.8) |
80 (61.1) |
70 (53.8) |
|||
| Non ductal |
6 (25) |
12 (50) |
11 (45.8) |
|||
| Lymph-node |
0.000 |
0.88 |
0.66 |
|||
| Negative |
4 (4,4) |
53 (58.9) |
46 (51.1) |
|||
| Positive |
24 (36.9) |
39 (60) |
35 (54.7) |
|||
| Tumor Grade |
0.072 |
0.000 |
0.000 |
|||
| 1–2 |
17 (14.8) |
83 (72.2) |
70 (61.4) |
|||
| 3 |
11 (27.5) |
9 (22.5) |
11 (27.5) |
|||
|
HER-2: Human epidermal growth factor receptor 2; ER: Estrogen receptor; PR: Progesterone receptor. | ||||||
Ayadi et al. World Journal of Surgical Oncology 2008 6:112 doi:10.1186/1477-7819-6-112 |
||||||